Bracco Imaging to acquire Blue Earth Diagnostics for $450 million

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

advertisement

 

Business Affairs Homepage

With stock value up 51 percent, is Mindray too pricey? Valuation has recently soared to $29 billion

Some medical devices exempted from China tariffs Among the recently announced, 110 exemptions

Consumer experience is top priority for 69 percent of US hospitals: survey Trend reflects growing patient burden in paying for services

Noritsu acquires R&F Imaging Systems Expands R&F presence from regional to national scale

Getting to 'yes' in enterprise imaging Tackling common problems on the road to more efficient radiology at SIIM

Canon hit with $32 million fine by EU for Toshiba deal Used tactic dubbed 'warehousing' to get around filing requirements

Change Healthcare's IPO now heading beyond $1 billion Offering 49 million shares at $19 each

IBM to pay $14.8 million to settle Maryland false claims allegations Settlement revolved around the 2011 acquisition by IBM of Cúram Software

Silicon Valley investor paints dire picture for future of radiologists Claims they should no longer exist in a decade

Installing and removing imaging equipment is no small task Expert insights on how project management is evolving

Bracco Imaging to acquire
Blue Earth Diagnostics

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million

by John R. Fischer , Staff Reporter
Bracco Imaging is set to acquire molecular imaging diagnostics enterprise, Blue Earth Diagnostics, from Syncona for $450 million.

The purchase of the British company’s outstanding shares includes an additional closing adjustment estimated at $25 million, and will make it a subsidiary of Bracco Imaging, though it will retain its well-known name.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"Bracco Imaging and Blue Earth Diagnostics have highly complementary capabilities and a shared commitment to providing high-quality diagnostic imaging solutions that enhance clinical management and advance patient care, making us a good fit," Fulvio Renoldi Bracco, chief executive officer of Bracco Imaging told HCB News. "Our customers will benefit from access to the enhanced capabilities, broadened portfolio of commercialized and developmental cancer agents for diagnostic and therapeutic use, and expanded commercial network of the combined organization."

The developer of Axumin (fluciclovine F 18), Blue Earth Diagnostics has obtained approval in both the EU and the U.S. for use of the molecular imaging agent in PET scans for the detection of suspected recurrent prostate cancer in men, with more than 50,000 doses administered to date in the U.S. alone.

It is currently investigating other potential applications in cancer imaging with 18F-Fluciclovine, including in neuro-oncology. And it recently acquired the exclusive, worldwide rights to a broad family of prostate specific membrane antigen (PSMA)-targeted radiohybrid (“rh”) agents, a clinical-stage, investigation class of theranostic compounds that could potentially be used in both imaging and treatment of prostate cancer.

The acquisition by Bracco Imaging is expected to expand Blue Earth Diagnostics in the more than 100 markets that the former currently operates in through subsidiaries, joint ventures, licenses and distribution partnership agreements. It holds a particularly big footprint in North America, China, Europe, Japan, Brazil, Mexico and South Korea, and boasts a research and development organization with a process-oriented approach and a track record in the diagnostic imaging industry.

"The combined business will leverage all of Bracco's leading diagnostic modalities and global footprint, along with an expanded suite of assets, including deepened PET imaging competencies, a strong portfolio of commercialized and developmental prostate cancer agents for diagnostic and therapeutic use, a developing franchise in brain tumors, expanded commercial infrastructure and deep financial resources," said Bracco.

The deal is anticipated to close during third quarter of the 2019 calendar year.

Business Affairs Homepage


You Must Be Logged In To Post A Comment